
"New Drug Offers Hope for Chronic Pain Relief, Study Reveals"
Researchers from Virginia Commonwealth University, the University of Texas at Austin, and the University of Virginia have developed a promising drug candidate, KT109, that targets the enzyme DAGLβ to reduce inflammation and alleviate chronic pain without the risk of addiction. The study, published in the Proceedings of the National Academy of Sciences, shows that the drug effectively tricks immune cells into shutting off inflammatory responses, offering a potential new treatment for chronic pain sufferers.

